What is Verge Genomics?
Founded in 2015 and headquartered in California, Verge Genomics is a biopharmaceutical company dedicated to revolutionizing drug discovery. The firm utilizes a unique, human-centric approach to identify therapeutic candidates, effectively bypassing the limitations of traditional animal models. By integrating large-scale genomic datasets with sophisticated artificial intelligence, the company aims to reduce the high failure rates typically associated with clinical development.
The company's market position is defined by its ability to bridge the gap between complex biological data and actionable clinical insights. As a leader in the digital health and data science space, Verge Genomics partners with major industry players to optimize biopharmaceutical operations, ensuring that its pipeline remains robust and responsive to unmet medical needs in areas such as neuroscience and immunology.
How much funding has Verge Genomics raised?
Verge Genomics has raised a total of $134.3M across 4 funding rounds:
Angel/Seed
$4M
Series A
$32M
Debt
$350K
Series B
$98M
Angel/Seed (2015): $4M with participation from Two Sigma Ventures, Karlin Ventures, Lerer Ventures, Draper Associates, Slow Ventures, and Great Oaks VC
Series A (2018): $32M led by DFJ
Debt (2020): $350K supported by PPP
Series B (2021): $98M featuring BlackRock, Vulcan, Lilly, Section 32, and Merck Global Health Innovation Fund
Key Investors in Verge Genomics
BlackRock
BlackRock is a global investment management firm that provides institutional clients with comprehensive asset management, risk management, and advisory services across diverse asset classes.
Lilly
Eli Lilly and Company is a global biopharmaceutical leader focused on the discovery and development of innovative medicines in areas such as oncology, immunology, and neuroscience.
Section 32
Section 32 is a venture capital firm founded by Bill Maris that specializes in investing in cutting-edge technology and supporting visionary entrepreneurs at the forefront of innovation.
What's next for Verge Genomics?
With the recent infusion of capital, Verge Genomics is well-positioned to scale its clinical operations and expand its therapeutic pipeline. The strategic focus will likely shift toward accelerating the transition of lead candidates into human clinical trials, while simultaneously enhancing the predictive capabilities of its AI-driven discovery engine. As the company matures, it will continue to leverage its network of institutional partners to navigate the complexities of global drug commercialization and regulatory approval processes.
The ongoing support from both venture capital firms and strategic biopharmaceutical partners suggests a long-term commitment to transforming the drug development lifecycle. Future growth will be contingent upon the successful validation of its platform in clinical settings, which remains the primary catalyst for long-term value creation in the biotechnology industry.
